Breast cancerEREndocrine resistancePredictive biomarkerPurpose Endocrine therapy is the standard treatment for oestrogen receptor positive (ER+) breast cancer. Despite its efficacy, around half of patients will develop resistance to this treatment and eventually relapse. Identification of effective and ...
Turner N C; Neven P; Loibl S;.Advances in the treatment of advanced oestrogen - receptor - positive breast cancer.Lancet.2016Turner NC, Neven P, Loibl S, Andre F. Advances in the treatment of advanced oestrogen-receptor positive ... NC Turner,P Neven,S Loibl,... - 《Lancet》 被引量...
Breast Cancer Research and Treatment Aims and scope Submit manuscript M. M. Roberts, R. A. Hawkins, F. E. Alexander, T. J. Anderson & R. J. C. Steele 22 Accesses 6 Citations Explore all metrics Summary In view of the possible introduction of screening programmes, this study ...
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project ra... Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel ...
Cancer Research UK and its commercial arm, Cancer Research Technology have developed a unique test to discover molecules that could lead to potential new treatments for oestrogen receptor (ER)-positive breast cancer.
Women with early-stage oestrogen receptor (ER)-positive (ER) breast cancer who receive standard endocrine therapy for 5 years remain at risk of distant recurrence for at least 15 years after treatment discontinuation. The extension of the duration of adjuvant endocrine therapy to 10 years has ...
ONCOLOGY:Long-term adjuvant anti-oestrogenic therapy for breast cancer Long-term (five years) adjuvant tamoxifen treatment for oestrogen receptor-positive, or ER-positive, breast cancer post-surgery is recognised as a major ad... BAC Jordan - 《Clinical Pharmacist》 被引量: 0发表: 2016年 Breas...
Ramchand, S. K., Lim, E., and Grossmann, M. (2016). Adjuvant endo- crine therapy in women with oestrogen-receptor-positive breast cancer: how should the skeletal and vascular side effects be assessed and managed? Clin. Endocrinol. (Oxf.) 85, 689-693. doi:10.1111/ CEN.13172...
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATL... Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces ...
Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Brea... Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-posi... ...